Automated Molecular Diagnostics Testing System Market

Automated Molecular Diagnostics Testing System Market Size and Share Forecast Outlook 2025 to 2035

The Automated Molecular Diagnostics Testing System Market is estimated to be valued at USD 2.5 billion in 2025 and is projected to reach USD 6.1 billion by 2035, registering a compound annual growth rate (CAGR) of 9.2% over the forecast period.

Quick Stats for Automated Molecular Diagnostics Testing System Market

• Automated Molecular Diagnostics Testing System Market Value (2025): USD 2.5 billion
• Automated Molecular Diagnostics Testing System Market Forecast Value (2035): USD 6.1 billion
• Automated Molecular Diagnostics Testing System Market Forecast CAGR: 9.2%
• Leading Segment in Automated Molecular Diagnostics Testing System Market in 2025: Hardware/Instruments (57.8%)
• Key Growth Regions in Automated Molecular Diagnostics Testing System Market: North America, Asia-Pacific, Europe
• Top Key Players in Automated Molecular Diagnostics Testing System Market: Roche Holding AG, Abbott Laboratories, Becton Dickenson & Company, Siemens Healthcare GmbH, Enigma Diagnostics Ltd, Qiagen, Bio-Rad Laboratories, Cepheid Inc., PerkinElmer Inc., AutoGenomics, ELITech Group

Automated Molecular Diagnostics Testing System Market Key Takeaways

Metric	Value
Automated Molecular Diagnostics Testing System Market Estimated Value in (2025 E)	USD 2.5 billion
Automated Molecular Diagnostics Testing System Market Forecast Value in (2035 F)	USD 6.1 billion
Forecast CAGR (2025 to 2035)	9.2%

Why is the Automated Molecular Diagnostics Testing System Market Growing?

The automated molecular diagnostics testing system market is witnessing strong growth momentum, driven by rising demand for rapid, accurate, and high-throughput diagnostic solutions across healthcare systems worldwide. Increasing prevalence of infectious diseases, cancer, and genetic disorders is creating a consistent need for advanced testing platforms capable of delivering precise results within shorter turnaround times. Automation is being prioritized by laboratories and hospitals to minimize human error, enhance reproducibility, and meet the growing volume of diagnostic testing.

Integration of robotics, artificial intelligence, and digital connectivity with molecular diagnostics is expanding capabilities and enabling real-time monitoring and data sharing across clinical networks. Additionally, the COVID-19 pandemic accelerated adoption of automated testing systems, establishing a long-term structural shift in diagnostics workflows.

Regulatory approvals for advanced automated solutions and growing investments in laboratory modernization are further reinforcing the market’s trajectory With the increasing importance of personalized medicine, companion diagnostics, and point-of-care testing, automated molecular diagnostic systems are anticipated to remain a cornerstone of modern healthcare, offering efficiency, accuracy, and scalability to meet evolving clinical demands.

Segmental Analysis

The automated molecular diagnostics testing system market is segmented by product type, application, technique, end user, and geographic regions. By product type, automated molecular diagnostics testing system market is divided into Hardware/Instruments and Software. In terms of application, automated molecular diagnostics testing system market is classified into Oncology, Genetic Engineering, Blood Screening, Microbiology, and Others. Based on technique, automated molecular diagnostics testing system market is segmented into PCR (Polymerase Chain Reaction), FISH (Fluorescent In-situ Hybridization), Spectral Karyotype Imaging, and DNA Microarrays. By end user, automated molecular diagnostics testing system market is segmented into Hospitals, Pathology Laboratories, Research Centers, Academic Institutions, and Commercial R&D Centers. Regionally, the automated molecular diagnostics testing system industry is classified into North America, Latin America, Western Europe, Eastern Europe, Balkan & Baltic Countries, Russia & Belarus, Central Asia, East Asia, South Asia & Pacific, and the Middle East & Africa.

Insights into the Hardware/Instruments Product Type Segment

The hardware and instruments segment is projected to account for 57.8% of the automated molecular diagnostics testing system market revenue share in 2025, making it the leading product type. Its dominance is being supported by the necessity of advanced platforms that integrate robotics, precision sensors, and high-throughput systems to conduct reliable diagnostic assays. These instruments are essential for enabling automation in sample preparation, amplification, detection, and data analysis, ensuring consistency and accuracy across high testing volumes.

Hospitals, research institutions, and diagnostic laboratories are increasingly prioritizing automated hardware to minimize manual intervention, reduce operational errors, and accelerate workflow efficiency. Technological advancements are enabling compact yet multifunctional instruments that support multiple assay types, enhancing versatility for end users.

Furthermore, continuous investments by manufacturers in developing scalable, modular hardware are reinforcing adoption across large and mid-sized laboratories As healthcare systems continue to demand reliable platforms capable of handling diverse diagnostic applications with improved turnaround times, the hardware and instruments segment is expected to maintain its leadership position in the market.

Insights into the Oncology Application Segment

The oncology application segment is anticipated to hold 30.5% of the automated molecular diagnostics testing system market revenue share in 2025, positioning it as the leading application area. Its leadership is being driven by the growing burden of cancer globally, which has necessitated advanced diagnostic tools for early detection, staging, and monitoring of disease progression. Automated molecular testing systems are enabling precise identification of genetic mutations, biomarkers, and molecular signatures that guide targeted therapy selection and personalized treatment planning.

The ability to provide accurate, reproducible results with high sensitivity is improving clinical outcomes and supporting oncology research efforts. Growing awareness about the importance of early cancer detection, coupled with investments in companion diagnostics for immunotherapy and targeted therapy, is boosting demand for automated platforms in oncology.

Furthermore, the integration of automation allows laboratories to scale cancer testing operations efficiently while maintaining compliance with regulatory standards As cancer incidence continues to rise, oncology-focused molecular diagnostics are expected to remain the most critical driver of system adoption globally.

Insights into the PCR Technique Segment

The PCR technique segment is expected to capture 29.8% of the automated molecular diagnostics testing system market revenue share in 2025, making it the leading technique. This dominance is being supported by the versatility, reliability, and accuracy of PCR in detecting a wide range of pathogens, genetic disorders, and oncology-related biomarkers. PCR’s established role in molecular diagnostics, combined with its ability to deliver high sensitivity even with low nucleic acid concentrations, is driving widespread use.

Automation has significantly enhanced PCR workflows by minimizing contamination risk, reducing turnaround times, and enabling simultaneous processing of large sample volumes. The segment is also benefiting from continuous advancements such as real-time PCR and digital PCR, which improve detection capabilities and support applications in clinical diagnostics, research, and public health.

PCR-based automated systems are being preferred due to their compatibility with existing laboratory infrastructure and regulatory validation across multiple regions With its proven reliability and adaptability to new diagnostic assays, PCR is expected to remain the cornerstone technique in automated molecular diagnostics testing.

Market Overview

Automated Molecular Diagnostics Testing System Market Overview

The technological developments in genetic engineering has created many new aspects in diagnostic sciences. The molecular diagnostic techniques are used for understanding the biological samples and their genetic code and figure out the irregularities caused in an individual's DNA.

The molecular diagnostic involves various techniques which are time consuming, costly and require expertise to perform. These techniques are also subjected to errors which may lead to wrong interpretation of data and loss of valuable test materials and time. To compensate this loss of time and money automated molecular diagnostic systems are required.

These systems run on computerized programs to carry out diagnostic processes on a given biological sample. These systems are highly effective and accurate. With the changing trend towards personalized medicine and developments in genetic engineering the automated molecular diagnostics testing system market is expected to boost during the forecast period.

The major drivers of automated molecular diagnostic system market are increasing demand for more number of healthcare facilities and diagnostics laboratories along with high adoption rate of automated molecular diagnostics testing systems.

The introduction of cloud based databases that are used by the automated molecular diagnostic testing systems to determine the samples is providing significant growth opportunities to automated molecular diagnostic testing system market.

The increasing demand of molecular diagnostics requires low time consuming techniques, this is providing traction for automated molecular diagnostics testing systems market. Along with low time cycle automated systems are also able to provide more information on samples and analyze multiple organisms for detection of infectious diseases.

However the high price of these systems and requirement of the highly skilled labor to use these systems is currently hampering the growth of automated molecular diagnostic testing systems market.

With the increasing demand for the automated molecular diagnostics testing systems and high cost of molecular diagnostics tests, several companies are trying to develop effective automated and self-contained, small sized analyzers at low cost. Also companies are trying to develop efficient and user friendly databases for automated systems

Geographically the automated molecular diagnostics testing system market is segmented into five regions: North America, Latin America, Europe, Asia Pacific and MEA region. North America and Europe are leading region in the automated molecular diagnostic market mainly due to higher adoption rate towards automation in the healthcare industry.

Also the rate of healthcare expenditure in North America and Europe is high along with demand for latest technology. The adoption rate of personalized medicine is also very high in the USA and EU5 countries which is boosting the automated molecular diagnostic testing market. APAC region is expected exhibit significant growth in terms of revenue over the forecast period.

The large number of research centers in China and India and R&D centers in Japan will lead to rise in demand for high quality of molecular diagnostics which is ultimately expected to boost the demand of automated molecular diagnostic testing systems in the APAC region during the forecast period.

Some key participants in the automated molecular diagnostic market are Roche Holding AG, Abbott Laboratories, Becton Dickenson & Company, Siemens Healthcare GmbH, Enigma Diagnostics Ltd., Qiagen, Bio-Rad Laboratories, Inc., Cepheid Inc. and PerkinElmer Inc., AutoGenomics, ELITech Group.

Automated Molecular Diagnostics Testing System Market Report Includes

• Automated Molecular Diagnostics Testing System Market Dynamics
• Historical Actual Market Size, 2025 - 2025
• Automated Molecular Diagnostics Testing System Market Size & Forecast 2025 to 2025
• Automated Molecular Diagnostics Testing System Market Current Trends/Issues/Challenges
• Competition & Companies involved
• Automated Molecular Diagnostics Testing System Market Drivers and Restraints

Regional analysis includes

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East & Africa

Analysis of Automated Molecular Diagnostics Testing System Market By Key Countries

Country	CAGR
China	12.4%
India	11.5%
Germany	10.6%
France	9.7%
UK	8.7%
USA	7.8%
Brazil	6.9%

Country-wise Analysis

The Automated Molecular Diagnostics Testing System Market is expected to register a CAGR of 9.2% during the forecast period, exhibiting varied country level momentum. China leads with the highest CAGR of 12.4%, followed by India at 11.5%. Developed markets such as Germany, France, and the UK continue to expand steadily, while the USA is likely to grow at consistent rates. Brazil posts the lowest CAGR at 6.9%, yet still underscores a broadly positive trajectory for the global Automated Molecular Diagnostics Testing System Market. In 2024, Germany held a dominant revenue in the Western Europe market and is expected to grow with a CAGR of 10.6%. The USA Automated Molecular Diagnostics Testing System Market is estimated to be valued at USD 887.4 million in 2025 and is anticipated to reach a valuation of USD 1.9 billion by 2035. Sales are projected to rise at a CAGR of 7.8% over the forecast period between 2025 and 2035. While Japan and South Korea markets are estimated to be valued at USD 119.8 million and USD 63.3 million respectively in 2025.

Key Players in the Automated Molecular Diagnostics Testing System Market

• Roche Holding AG
• Abbott Laboratories
• Becton Dickenson & Company
• Siemens Healthcare GmbH
• Enigma Diagnostics Ltd
• Qiagen
• Bio-Rad Laboratories
• Cepheid Inc.
• PerkinElmer Inc.
• AutoGenomics
• ELITech Group

Scope of the Report

Item	Value
Quantitative Units	USD 2.5 Billion
Product Type	Hardware/Instruments and Software
Application	Oncology, Genetic Engineering, Blood Screening, Microbiology, and Others
Technique	PCR (Polymerase Chain Reaction), FISH (Fluorescent In-situ Hybridization), Spectral Karyotype Imaging, and DNA Microarrays
End User	Hospitals, Pathology Laboratories, Research Centers, Academic Institutions, and Commercial R&D Centers
Regions Covered	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Covered	United States, Canada, Germany, France, United Kingdom, China, Japan, India, Brazil, South Africa
Key Companies Profiled	Roche Holding AG, Abbott Laboratories, Becton Dickenson & Company, Siemens Healthcare GmbH, Enigma Diagnostics Ltd, Qiagen, Bio-Rad Laboratories, Cepheid Inc., PerkinElmer Inc., AutoGenomics, and ELITech Group

Automated Molecular Diagnostics Testing System Market by Segments

Product Type:

• Hardware/Instruments
• Software

Application:

• Oncology
• Genetic Engineering
• Blood Screening
• Microbiology
• Others

Technique:

• PCR (Polymerase Chain Reaction)
• FISH (Fluorescent In-situ Hybridization)
• Spectral Karyotype Imaging
• DNA Microarrays

End User:

• Hospitals
• Pathology Laboratories
• Research Centers
• Academic Institutions
• Commercial R&D Centers

Region:

• North America
  • USA
  • Canada
  • Mexico
• Latin America
  • Brazil
  • Chile
  • Rest of Latin America
• Western Europe
  • Germany
  • UK
  • Italy
  • Spain
  • France
  • Nordic
  • BENELUX
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • Hungary
  • Balkan & Baltic
  • Rest of Eastern Europe
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia & New Zealand
  • Rest of South Asia and Pacific
• Middle East & Africa
  • Kingdom of Saudi Arabia
  • Other GCC Countries
  • Turkiye
  • South Africa
  • Other African Union
  • Rest of Middle East & Africa